Protein Purification Technologies banner

The booming field of biologics places ever greater challenges on protein purification. As more of these recombinant proteins are developed even greater demand falls on achieving pure protein, either for research or for therapeutic development. Achieving pure protein quicker and cheaper is essential, while also ensuring protein quality. The Protein Purification Technologies conference brings together international experts who share their best practices and strategies for optimising this ubiquitous task. Emphasis is given to the technologies that support purification and how they are constantly being innovated, renovated, and revised to keep up with the industry’s growing demands.

Sunday, 13 November

Recommended Short Courses*14:00

SC3: Use and Troubleshooting of Eukaryotic Expression Systems 

*Separate registration required. See short courses page for details.

Wednesday, 16 November

Registration and Morning Coffee (Garden Room)07:30




Chairperson's Opening Remarks

Nicola Burgess-Brown, PhD, Director of Enzymology and Protein Engineering, Exact Sciences Innovation


Recombinant Proteins as Intermediate Reagents: Final Applications Will Require Alternative Protocol Design and Quality Controls

Ario De Marco, Associate Professor, Lab for Environmental & Life Sciences, University of Nova Gorica

Data reliability is a cornerstone of scientific work and the process to improve good practices for the evaluation and report of experimental results has been constant. Due to the extremely large variety of potentially alternative protocols, the identification of minimal sets of meaningful and implementable analyses suitable for recombinant protein quality assessment has been complicated. Further tests might become necessary when proteins are used for specific applications. As 1) protein quality evaluation should become a routine practice 2) specific applications require further analyses and 3) quality controls should be not perceived as a burden.


Sane in the Membrane – The Salipro Platform for GPCRs and Ion Channels for Drug Development

Jens Frauenfeld, PhD, Founder & CEO, Salipro Biotech AB

Membrane proteins are important drug targets (GPCRs, ion channels), yet are notoriously difficult to work with. We’ll present case studies on our latest research on the prominent drug targets CXCR4 and TRPV3 with direct extraction from crude cell membranes into lipid Salipro particles. This direct approach enables entirely new possibilities for de novo development and characterisation of biologics and small molecules, including phage display, B cell sorting, and cryoEM.

09:30 How a Single Protein Tag Provides a Platform for Key Processes in Antibody Production

Fabian Mohr, PhD, Vice President Research & Development, IBA Lifesciences GmbH

Antibodies play an important role in immune responses and serve as treatment options for infections or diseases. The identification of well-working antibodies is a complex procedure involving several different steps: the initial production of the antigen, immunization of a host, retrieving the produced antibodies and screening for promising candidates.  A protein tag can provide options to centralize these steps onto one platform, making the entire process more time- and cost-effective.

Coffee Break in the Exhibit Hall with Poster Viewing (Verdi and Vivaldi 1&2)10:00


Enhanced Stability of Detergent-Free Human Native STEAP1 Protein from Neoplastic Prostate Cancer Cells upon an Innovative Isolation Procedure

Luis Passarinha, PhD, Assistant Professor, Health Sciences Research Centre, Universidade da Beira Interior

The STEAP1 is a cell-surface antigen over-expressed in prostate cancer, which contributes to tumor progression and aggressiveness. However, the molecular mechanisms underlying STEAP1 and its structural determinants remain elusive. Here, the fraction capacity of hydrophobic matrices on LNCaP lysates was evaluated followed by a Co-Immunoprecipitation (Co-IP) polishing. Several stabilizing additives were assessed, and the melting temperature (Tm) values ranked the best/worst compounds. A single step demonstrated higher selectivity of Butyl-Sepharose for cells impurities removal. Co-IP allowed to recover pure fraction of STEAP1. Tm of ~55ºC was determined and an a-helical structure was identified, confirming STEAP1 stability in the purification buffer.


Accelerating Drug Discovery: A Refresh of the Lead Panel Generation Phase within Biopharm Discovery

Edward Coulstock, PhD, Associate Fellow & Scientific Leader, BMPD MDE, GlaxoSmithKline

This presentation discusses GSK’s refinement of the Lead Panel mAb generation stage as part of our revised End-to-End approach to keep the discovery funnel wider, for longer; to enable us to express and purify panels of antibodies in a high-throughput, semi-automated manner; to enable parallel prosecution of biological and developability screens, thereby accelerating our drug discovery process.


Why you Need Both Crystallography and EM to Study GPCRs and Design Drugs, and How to Get There

Andreas G. Plueckthun, PhD, Professor & Head, Biochemistry, University of Zurich

We developed several technologies that allow G-protein coupled receptors to be functionally expressed at much higher levels in a variety of hosts, and increase their stability. This has permitted us to determine structures of several receptors by both X-ray crystallography and cryo-electron microscopy, allowing us to study the full conformational range from inverse agonists to full agonists with and without trimeric G proteins, uncovering important aspects of drug structure and activity.

12:15 Automated, Integrated Workflows for Purification Process Development of New Molecular Formats

Jean Aucamp, Associate Director, R&D, Biologics • Research and Development, Lonza

New molecular formats (NMF) cover a multitude of therapeutic protein modalities of increased structural complexity.  Diverse, yet unique, challenges are encountered with these entities during purification process development. Lonza developed a modular toolbox approach to meet these challenges. This presentation will focus on automated medium and high throughput workflows which were established for the rapid and reliable execution of early-phase development screens.

Session Break12:45

12:50 TurboCHO Antibody Expression: For when Faster Speed and Higher Quality Matters

Robert Ford, PhD, Field Application Scientist, Commercial, GenScript Biotech (Netherlands) B.V.

Recombinant antibody expression in mammalian cells is crucial to ensure the reliable supply and batch-to-batch consistency of potential antibody drugs. The challenges of antibody expression projects are: 1) insufficient antibody yield 2) long time to completion 3) budget overruns. To ease these pain-points, GenScript has launched its proprietary TurboCHO platform, which offers higher yield performance within a shorter time period to support all stages of the drug development pipeline.

13:20 Streamlining Biotherapeutic Development Programs with Next-Generation Transposon Vectors

Ana Rebocho, PhD, R&D Manger, Bioproduction, Horizon Discovery

The Horizon’s CHOSOURCE expression platform has been recently improved by the introduction of the new CHOSOURCE TnT transposon technology. The TnT expression system takes advantage of transposases that allow the generation of stable high producing clones. The partnership of CHOSOURCE TnT with CHOSOURCE cell lines enables the implementation of a robust and safe cell line development pipeline with high productivity and stability, contributing to the acceleration of biologic development programs.

Dessert Break in the Exhibit Hall & Last Chance for Poster Viewing (Verdi and Vivaldi 1&2)13:50

Breakout Discussions14:45

Breakout Discussions are informal, moderated, small-group discussions, allowing participants to exchange ideas and experiences and develop future collaborations around a focused topic. Each discussion will be led by a facilitator who keeps the discussion on track and the group engaged. For in-person events, the facilitator will lead while sitting with delegates around a table. For virtual attendees, the format will be in an online networking platform. To get the most out of this format, please come prepared to share examples from your work, be a part of a collective, problem-solving session, and participate in active idea sharing. 


Transient Protein Production Challenges IN PERSON ONLY

Richard Altman, MS, Field Application Scientist, Life Science Solutions, Thermo Fisher Scientific

Transient protein production in mammalian cells continues its evolution as an integral part of the biotherapeutic drug discovery process as well as an important tool to generate recombinant proteins for a variety of other applications. We discuss challenges facing researchers as they try to meet an expanding demand for transiently produced recombinant protein.         ​

  • What are the current challenges to transient protein production?         
  • How do we optimize the whole protein expression process?         
  • What parameters can impact the quality or physical attributes of transiently produced proteins?

High-Throughput (HTP) Protein Production IN PERSON ONLY

Nicola Burgess-Brown, PhD, Director of Enzymology and Protein Engineering, Exact Sciences Innovation

  • Benefits of testing multiple constructs in parallel.​
  • HTP cloning or gene synthesis?
  • HTP expression screening in multiple hosts: What scale, conditions, equipment, readout?
  • How to screen intracellular, secreted and membrane proteins in HTP?
  • Choice of purification tags for HTP screening.
  • Challenges of working in HTP: What conditions to test first to increase success?



Chairperson's Remarks

Dennis Karthaus, PhD, Manager, Media and Processes, Sartorius Xell GmbH


Novel Strategies for Development of Affinity Purification Platforms

Sophia Hober, PhD, Professor, School of Biotechnology, KTH Royal Institute of Technology

Due to the costly and time-consuming production of biological drugs, selective affinity purification methods are desirable. To achieve effective elution from the matrix when purifying by affinity-based methods, low pH is commonly used. These harsh elution conditions might cause the formation of aggregates and thereby greatly compromise the yield of the target protein, which can be a major problem for many biologic drugs. Therefore, combinatorial libraries for selection of ion-dependent high-affinity binders have been designed. These libraries and how to utilize them for selection and development of specific and efficient protein purification methods will be presented. 


Design and Discovery of Affinity and Mixed-mode Adsorbents

Cecilia Roque, PhD, Associate Professor in Bioengineering, NOVA University of Lisbon

Small synthetic compounds, tailor-made for selected biological targets, can be used as ligands in bioseparation. In this talk, we will show how rationally designed chemical combinatorial libraries support the development of robust peptidomimetics that can be easily adapted to several targets and to chromatographic and non-chromatographic methods.

16:30 Simple Reactions – Radical Results; Cell-Free Protein Production Scaled According to Customer’s Needs

Ricarda Finnern, PhD, CSO, LenioBio GmbH

ALiCE is a eukaryotic cell-free protein synthesis system that can be used to rapidly produce complex proteins at high yield and at a scale useful to protein manufacturing. We present case studies of cytosolic and microsomally expressed proteins produced by ALiCE, and describe their subsequent purification and characterization.


Purification of a Peptide Tagged Protein via an Affinity Chromatographic Process with Underivatized Silica

Friederike Eilts, PhD, Research Associate, Bioseparation Engineering Group, Mechanical Engineering, Technical University of Munich

In biotechnology, the use of a histidine tag that is molecularly fused to a target protein and forms a selective coordinative bond with traditional IMAC, NTA, or IDA functionalized materials to analyze and purify proteins quickly and specifically is well established. This talk introduces a new peptide tag that enables a novel affinity purification technique using underivatized silica.


Protein Tag Technology toward the Sustainable Production of Protein-Engineered Materials

Tatiana Q. Aguiar, PhD, Postdoc, Centre of Biological Engineering, University of Minho

The utilization of proteins to engineer materials has allowed the development of novel and advanced functional materials with great promise for broad applications. To guarantee the sustainable manufacturing of advanced protein-engineered materials, protein tag-mediated strategies that combine the purification and immobilization of recombinant proteins/peptides onto/into natural, synthetic, or hybrid materials in a single step are arising and attracting increasing interest. This talk will address progresses and challenges in this field.


Purification Tag Technologies


Dennis Karthaus, PhD, Manager, Media and Processes, Sartorius Xell GmbH


Tatiana Q. Aguiar, PhD, Postdoc, Centre of Biological Engineering, University of Minho

Friederike Eilts, PhD, Research Associate, Bioseparation Engineering Group, Mechanical Engineering, Technical University of Munich

Nicola Burgess-Brown, PhD, Director of Enzymology and Protein Engineering, Exact Sciences Innovation

Close of Summit18:30